{
"endpoint": "pubmed-search",
"count": 1,
"truncated": true,
"took_ms": 2300,
"items": [
{
"recordType": "paper",
"pmid": "41931049",
"doi": null,
"title": "GLP-1 Receptor Agonists.",
"abstract": "Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and direct effects on hypothalamic nuclei to enhance satiety (which promotes weight loss). Beyond the impressive effects of GLP-1 receptor agonists on blood glucose levels and body weight, large-scale randomized, controlled trials have shown that GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes. Adverse side effects from GLP-1 receptor agonists are mostly gastrointestinal but may also include loss of muscle and bone mass. Questions remain about long-term adherence, weight regain after discontinuation of treatment, and the functional implications of the loss of muscle and bone mass. Recent and ongoing targeted studies suggest the possibility of additional uses for GLP-1 receptor agonists.",
"authors": [
"Clifford J Rosen",
"Julie R Ingelfinger"
],
"authorCount": 2,
"firstAuthor": "Clifford J Rosen",
"journal": "The New England journal of medicine",
"journalAbbrev": "N Engl J Med",
"issn": "1533-4406",
"year": "2026",
"pubDate": "2026-04-02",
"volume": "394",
"issue": "13",
"pages": "1313-1324",
"pubTypes": [
"Journal Article",
"Review"
],
"meshTerms": [
"Humans",
"Cardiovascular Diseases",
"Diabetes Mellitus, Type 2",
"Glucagon-Like Peptide 1",
"Glucagon-Like Peptide-1 Receptor Agonists",
"Hypoglycemic Agents",
"Incretins",
"Obesity",
"Renal Insufficiency",
"Anti-Obesity Agents",
"Disease Progression",
"Gastric Emptying",
"Glucagon",
"Gastrointestinal Microbiome",
"Satiety Response",
"Randomized Controlled Trials as Topic",
"Medication Adherence"
],
"keywords": null,
"pmcId": null,
"url": "https://pubmed.ncbi.nlm.nih.gov/41931049/",
"scrapedAt": "2026-11-22T19:07:40.526Z"
}
]
}
curl --location --request GET 'https://zylalabs.com/api/14840/pubmed+search+api/38492/search+pubmed+articles?query=GLP-1 obesity trial&sort=relevance&includeMesh=true&limit=2' --header 'Authorization: Bearer YOUR_API_KEY'
注册后,每个开发者都会被分配一个个人 API 访问密钥,这是一个唯一的字母和数字组合,用于访问我们的 API 端点。要使用 PubMed 搜索 API 进行身份验证,只需在 Authorization 标头中包含您的 bearer token。
| 标头 | 描述 |
|---|---|
授权
|
必需
应为 Bearer access_key. 订阅后,请查看上方的"您的 API 访问密钥"。
|
搜索 PubMed 并以 JSON 格式返回文章,包括 PMID、摘要、作者、期刊详细信息、MeSH 术语和出版类型
不。响应包含摘要和书目信息字段,如果文章在 PubMed Central 中有存档,还会包含 pmcId。检索和阅读全文是调用方需要单独执行的步骤。
是的,可以直接通过查询实现,因为支持完整的 PubMed 搜索语法:在搜索词中添加出版类型子句。这样,每条返回的记录都会在 pubTypes 数组中重复显示分类,便于之后筛选
这些字段只有在 PubMed 收录时才存在:许多较早发表或未被索引的文章没有 DOI,大多数文章未存入 PubMed Central,而且大多数记录都没有作者关键词,其索引信息存在 meshTerms 中
Year 是四位数的出版年份,pubDate 是完整的出版日期,例如四月中的某一天。两者都会返回,因为引用格式需要年份,而信息流和时间线需要具体日期。
不,它按发表日期排序,而不是按 PubMed 收录文章的时间排序。因此,一篇非常新的文章排名可能低于一篇收录时间更晚的较旧文章,这就是为什么 dateFrom 筛选器是严格限定时间范围更稳妥的工具